More thoughts on the reporting of adverse events in cancer clinical trials [12]

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 918-

  Extermann, Martine ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN;

BLOOD CELL COUNT; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; DRUG SAFETY; HEMATOLOGIC DISEASE; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; DRUG SURVEILLANCE PROGRAM; NOTE; PHASE 2 CLINICAL TRIAL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CLINICAL TRIALS, PHASE II; HUMANS;

EID: 33947522508     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.3948     Document Type: Letter

References (5)

1. Scharf O, Colevas AD: Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 24:3933-3938, 2006
2. Anderson SJ: Some thoughts on the reporting of adverse events in phase II cancer clinical trials. J Clin Oncol 24:3821-3822, 2006
3. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
4. Nabholtz JM, Falkson C, Campos D, et al: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975, 2003
5. Gómez H, Hidalgo M, Casanova L, et al: Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis. J Clin Oncol 16:2065-2069, 1998